Erythropoietin and acute renal failure.
The hemopoietic growth factor erythropoietin (EPO) has been recognized to be a multifunctional cytokine that plays a key role in ischemic preconditioning in the brain and heart. The EPO receptor is expressed widely in the kidney, and we review the important findings from the use of EPO in experimental models of acute renal failure that show that EPO reduces tubular cell death and hence the dysfunction induced by ischemia reperfusion injury, and we explore how these observations may be translated into the clinical arena.
Sharples
Edward J
EJ
Center for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary, University of London, London, UK. edsharps@doctors.org.uk
Yaqoob
Muhammad M
MM
D058186:Acute Kidney Injury / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000293:injuries; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000473:pathology; D011994:Recombinant Proteins; D015427:Reperfusion Injury / Q000188:drug therapy
D011994:Recombinant Proteins; D004921:Erythropoietin